Fluid and Electrolyte Disorders in Cancer Patients
1 Kidney Function
2 Dysnatremias in Cancer
3 Potassium Disorders
4 Calcium and Phosphorus Disorders
5 Volume Disorders and Fluid Resuscitation
Paraprotein-Related Kidney Diseases
7 Cast Nephropathy
8 Systemic Light Chain Amyloidosis
9 Monoclonal Immunoglobulin Deposition Disease
10 Fibrillary and Immunotactoid Glomerulonephritis
Hematopoietic Stem Cell Associated Kidney Disease
11 Hematopoietic Cell Transplant Associated Kidney Injury
12 Sinusoidal Obstruction Syndrome
13 Thrombotic Microangiopathy
14 Graft-Versus-Host Disease
15 Chronic Kidney Disease, End-Stage Renal Disease, and Bone Marrow Transplant
Chemotherapy and Radiation Related Kidney Diseases
16 Conventional Chemotherapy
17 Targeted Cancer Therapies (Biologics)
18 Adverse Kidney Effects of Immunotherapies
19 Chemotherapy in Chronic Kidney Disease and Dialysis
20 Radiation Nephropathy
21 Paraneoplastic Glomerular Diseases
22 Paraneoplastic Glomerulonephritis
23 Hematologic Malignancies
24 Cancer Screening Recommendations
25 Renal Cell Cancer
26 Wilms Tumor and von Hippel Lindau Disease
27 Tuberous Sclerosis Complex and the Kidney
28 Evaluation of a Renal Cyst/Mass
Acute Kidney Injury
29 Acute Kidney Injury Incidence, Pathogenesis, and Outcomes
30 Tumor Lysis Syndrome
31 Obstructive Nephropathy in Cancer
32 Renal Replacement Therapies
Chronic Kidney Disease and Cancer
33 Chronic Kidney Disease as a Complication of Cancer, With Special Focus on Kidney and Urothelial Tumors
34 Incidence of Cancer and Screening Recommendations
35 Cancer in Renal Transplant Patients
36 Renal Infections in Cancer Patients
37 Kidney Disease in Leukemia
38 Kidney Disease in Lymphoma
Kidney disease and cancer are frequent comorbidities that require specialized knowledge and expertise from both the nephrologist and the oncologist. Written by three pioneers in this growing subspecialty, Onco-Nephrology provides authoritative, definitive coverage of the mechanism and management of these two life-threatening diseases. This unique, single-volume resource covers current protocols and recommends management therapies to arrest kidney failure and allow oncologic treatments to continue and succeed.
- Addresses acute and chronic kidney diseases that develop from a variety of cancers. This includes direct kidney injury from the malignancy, paraneoplastic effects of the cancer, and various cancer agents used to treat the malignancy.
- Discusses key issues regarding kidney disease in patients with cancer, including conventional chemotherapeutic regimens and new novel therapies (targeted agents and immunotherapies) or the malignancies themselves that may promote kidney injury; patients with chronic kidney disease who acquire cancer unrelated to renal failure; and kidney transplantation, which has been shown to carry an increased risk of cancer.
- Contains dedicated chapters for each class of the conventional chemotherapeutic agents, targeted cancer agents, and cancer immunotherapies including the basic science, pathogenic mechanisms of injury, clinical manifestations, and treatment.
- Includes special chapters devoted to the individual classes of chemotherapies that relate to kidney disease for quick reference. Discusses increasingly complex problems due to more numerous and specialized anti-cancer drugs, as well as increased survival rates for both cancer and renal failure requiring long-term patient care.
- Covers anti-VEGF (antivascular endothelial growth factor) agents and cancer immunotherapies - treatments that are being recognized for adverse kidney effects.
- Utilizes a clear, logical format based on the ASN Core Curriculum for Onco-Nephrology, making this reference an excellent tool for board review, as well as a practical resource in daily practice.
- Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.
By Kevin W. Finkel, Professor and Clinical Vice-Chairman of Medicine; Director, Division of Renal Diseases & Hypertension; Chief, Section of Critical Care Nephrology, University of Texas Medical School, Houston, TX, USA ; Mark Anthony Perazella, MD and Eric P Cohen, MD, Professor, University of Maryland School of Medicine, Baltimore, Maryland